Analyst consensus rating

Lyell Immunopharma Analyst Rating: Buy

Direct answer

Lyell Immunopharma's consensus rating is Buy.

8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $37.63.
Forecast evidence checked November 21, 2026.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$13.80
Average price target
$37.63
High price target
$49.00
Low price target
$12.00
Low target gap
-13%
Target upside
+172.6%
High target gap
+255.1%
Target range width
268.1%
Consensus rating
Buy
Analysts
8
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Lyell Immunopharma?

Lyell Immunopharma has a verified Buy consensus. The same dataset has an average price target of $37.63.

How far are Lyell Immunopharma's low and high targets from the recorded price?

The low target implies -13%, while the high target implies +255.1%.

How many analysts are included in Lyell Immunopharma's consensus?

The verified consensus includes 8 analysts.

How is Lyell Immunopharma's target upside or downside calculated?

The average target of $37.63 is divided by the recorded price of $13.80, then one is subtracted to produce +172.6%. This does not guarantee a future return.

When was Lyell Immunopharma's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.